| Literature DB >> 29158190 |
Renato M Lupinacci1, Anastasia Goloudina2, Olivier Buhard3, Jean-Baptiste Bachet4, Raphaël Maréchal5, Pieter Demetter6, Jérôme Cros7, Armelle Bardier-Dupas8, Ada Collura9, Pascale Cervera10, Aurélie Scriva11, Sylvie Dumont12, Pascal Hammel13, Alain Sauvanet14, Christophe Louvet15, Jean-Robert Delpéro16, François Paye17, Jean-Christophe Vaillant18, Thierry André19, Jean Closset5, Jean-François Emile20, Jean-Luc Van Laethem5, Vincent Jonchère3, Issam Abd Alsamad21, Martine Antoine22, Anita Rodenas22, Jean-François Fléjou10, Nelson Dusetti23, Juan Iovanna23, Alex Duval24, Magali Svrcek25.
Abstract
Microsatellite instability (MSI) caused by mismatch repair deficiency (dMMR) is detected in a small proportion of pancreatic ductal adenocarcinomas (PDACs). dMMR and MSI have been associated with responses of metastatic tumors, including PDACs, to immune checkpoint inhibitor therapy. We performed immunohistochemical analyses of a 445 PDAC specimens, collected from consecutive patients at multiple centers, to identify those with dMMR, based on loss of mismatch repair proteins MLH1, MSH2, MSH6, and/or PMS2. We detected dMMR in 1.6% of tumor samples; we found dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02). PDACs with dMMR contained potentially immunogenic mutations because of MSI in coding repeat sequences. PDACs with dMMR or MSI had a higher density of CD8+ T cells at the invasive front than PDACs without dMMR or MSI (P = .08; Fisher exact test). A higher proportion of PDACs with dMMR or MSI expressed the CD274 molecule (PD-L1, 8/9) than PDACs without dMMR or MSI (4/10) (P = .05). Times of disease-free survival and overall survival did not differ significantly between patients with PDACs with dMMR or MSI vs without dMMR or MSI. Studies are needed to determine whether these features of PDACs with dMMR or MSI might serve as prognostic factors.Entities:
Keywords: Cytokine Production; Marker; Pancreatic Cancer; T-cell Activation
Mesh:
Substances:
Year: 2017 PMID: 29158190 DOI: 10.1053/j.gastro.2017.11.009
Source DB: PubMed Journal: Gastroenterology ISSN: 0016-5085 Impact factor: 22.682